Evidence map›Paper›PMID 36854903›Full record

ArticleCardiovascular and interventional radiology2023

Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series.

Shanmukha Srinivas, Steven C Rose, Omar Al Jammal, Lee J Hsieh, Helena D Rockwell, David P Duncan, Jeet Minocha, Zachary T Berman

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Shanmukha SrinivasDepartment of Radiology, University of California Los Angeles, 757 Westwood Plaza, Los Angeles, CA, 92095, USA.ORCID http://orcid.org/0000-0002-8556-4563
Steven C RoseDepartment of Radiology, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Omar Al JammalDepartment of Radiology, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Lee J HsiehDepartment of Radiology, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Helena D RockwellDepartment of Radiology, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
David P DuncanDepartment of Radiology, Vanderbilt University, 1161 21st Avenue, South Nashville, TN, 37232, USA.
Jeet MinochaDepartment of Radiology, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Zachary T BermanDepartment of Radiology, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA. zberman@health.ucsd.edu.
University of California San Diego · USUniversity of California, Los Angeles · USVanderbilt University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the tumor response rates and liver toxicity of boosted-dose transarterial radioembolization (TARE) for treatment of hepatocellular carcinoma (HCC) refractory to previous transarterial embolization (TAE) and/or chemoembolization (TACE). MATERIALS AND

methodsAll patients were identified who had HCC treated between 2017 and 2020 that had been refractory to prior TAE or TACE, then treated with boosted-dose segmental or lobar TARE. Tumor response was assessed by multiphasic CT or MRI using localized mRECIST imaging criteria and serological alpha-fetoprotein levels at three and six months after TARE, if available. Liver toxicity was evaluated using serial serological liver function tests, platelet counts, and clinical Child-Pugh and MELD scores.

resultsTwenty-four patients met inclusion criteria. Mean age was 68.7 years (54-89); 8 were females. Three (12.5%) patients had Barcelona Clinical Liver Cancer stage A, 4 (16.7%) stage B, and 17 (70.8%) stage C disease. Three months after TARE, 52% of patients had a complete response and 33% had a partial response. Mean AFP decreased from 33.2 ng/mL at baseline to 17 ng/mL at 3 months (p = 0.782). The median MELD-Na score increased from 11 at baseline to 16 at 6 months post-TARE (p = 0.044); the mean Child-Pugh score rose from 5 at baseline to 6 at 3 months post-TARE (p < 0.01).

conclusionBoosted-dose TARE resulted in statistically significant favorable tumor responses by imaging criteria in 85% of patients previously refractory to TAE or TACE. TARE resulted in transient but acceptable deterioration of liver function and clinical scores.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsAgedFemaleHumansMalePneumonectomyRetrospective StudiesYttrium RadioisotopesYttrium-90Yttrium RadioisotopesHepatic artery embolizationHepatocellular carcinomaMedical internal radiation dose modelTransarterial chemoembolizationTransarterial radioembolization

Identifiers

PMID36854903
OpenAlexW4322624839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.